MY139102A - Substituted n-aryl heterocycles, process for their preparation and their use as medicaments - Google Patents

Substituted n-aryl heterocycles, process for their preparation and their use as medicaments

Info

Publication number
MY139102A
MY139102A MYPI20040479A MYPI20040479A MY139102A MY 139102 A MY139102 A MY 139102A MY PI20040479 A MYPI20040479 A MY PI20040479A MY PI20040479 A MYPI20040479 A MY PI20040479A MY 139102 A MY139102 A MY 139102A
Authority
MY
Malaysia
Prior art keywords
substituted
preparation
medicaments
aryl heterocycles
compounds
Prior art date
Application number
MYPI20040479A
Other languages
English (en)
Inventor
Lothar Dr Schwink
Siegfried Dr Stengelin
Matthias Dr Gossel
Thomas Dr Boehme
Gerhard Dr Hessler
Petra Dr Stahl
Dick Dr Gretzke
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32841665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY139102(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MY139102A publication Critical patent/MY139102A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
MYPI20040479A 2003-02-14 2004-02-13 Substituted n-aryl heterocycles, process for their preparation and their use as medicaments MY139102A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10306250A DE10306250A1 (de) 2003-02-14 2003-02-14 Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
MY139102A true MY139102A (en) 2009-08-28

Family

ID=32841665

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20040479A MY139102A (en) 2003-02-14 2004-02-13 Substituted n-aryl heterocycles, process for their preparation and their use as medicaments

Country Status (29)

Country Link
EP (1) EP1597228A2 (fr)
JP (1) JP2006517563A (fr)
KR (1) KR20050101215A (fr)
CN (1) CN100506792C (fr)
AR (1) AR044496A1 (fr)
AU (1) AU2004212145B2 (fr)
BR (1) BRPI0407504A (fr)
CA (1) CA2516118A1 (fr)
CO (1) CO5690548A2 (fr)
DE (1) DE10306250A1 (fr)
EC (1) ECSP055967A (fr)
HR (1) HRP20050710A2 (fr)
MA (1) MA27735A1 (fr)
MX (1) MXPA05008449A (fr)
MY (1) MY139102A (fr)
NO (1) NO20054220L (fr)
NZ (1) NZ541823A (fr)
OA (1) OA13027A (fr)
PA (1) PA8595901A1 (fr)
PE (1) PE20040952A1 (fr)
PL (1) PL378065A1 (fr)
RS (1) RS20050666A (fr)
RU (1) RU2005128551A (fr)
TN (1) TNSN05194A1 (fr)
TW (1) TW200510297A (fr)
UA (1) UA86760C2 (fr)
UY (1) UY28186A1 (fr)
WO (1) WO2004072025A2 (fr)
ZA (1) ZA200506369B (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
CA2526285A1 (fr) 2003-05-15 2004-12-23 Arqule, Inc. Inhibiteurs de p38 et leurs methodes d'utilisation
ES2327684T3 (es) 2003-07-24 2009-11-02 Euro-Celtique S.A. Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor.
PL1867644T3 (pl) * 2003-07-24 2009-10-30 Euro Celtique Sa Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
EP1657240A4 (fr) 2003-08-18 2009-04-08 Fujifilm Finechemicals Co Ltd Pyridyltetrahydropyridines, pyridylpiperidines et leur methode de preparation
DE10360745A1 (de) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004003812A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
WO2006010082A1 (fr) * 2004-07-08 2006-01-26 Arqule, Inc. Naphtalenes disubstitues en position 1,4 utilises comme inhibiteurs de map kinase p38
WO2006022442A1 (fr) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. Nouveaux derives d’amides heterocycliques ayant une activite d’inhibition de la dihydroorotate deshydrogenase
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1799667B1 (fr) * 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
CA2582327A1 (fr) * 2004-10-01 2006-04-13 Takao Suzuki Compose heterocyclique azote substitue en 2 par un groupement arylcarboxamide
ES2336130T3 (es) 2004-10-18 2010-04-08 Eli Lilly And Company Derivados 1-(hetero)aril-3-amino-pirrolidina para uso como antagonistas del receptor de mglur3.
CA2584368A1 (fr) 2004-10-19 2006-04-27 Arqule, Inc. Synthese d'inhibiteurs d'imidazo-oxazole et d'imidazothiazole de la map kinase p38
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
US8084492B2 (en) * 2004-11-19 2011-12-27 The New Industry Research Organization Benzofuran compound and pharmaceutical composition containing the same
WO2006074025A1 (fr) 2004-12-30 2006-07-13 Janssen Pharmaceutica N.V. Urees piperazinyle et piperidinyle en tant que modulateurs de l’amide hydrolase d’acides gras
WO2006081389A1 (fr) 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Composes de thiophene utilises contre l'inflammation et les troubles lies a l'immunite
JP4870163B2 (ja) 2005-09-30 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー Ｍｃｈ受容体アンタゴニストとしてのインダン誘導体
CN102633783A (zh) * 2006-02-10 2012-08-15 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
AU2007214708A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
AU2007214710A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
JP5182088B2 (ja) * 2006-04-19 2013-04-10 アステラス製薬株式会社 アゾールカルボキサミド誘導体
KR101464385B1 (ko) 2006-04-19 2014-11-21 노파르티스 아게 ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
MX2008014290A (es) 2006-05-08 2008-11-26 Ariad Pharma Inc Compuestos heteroarilicos monociclicos.
BRPI0710328A2 (pt) 2006-05-08 2011-08-09 Ariad Pharma Inc composto da fórmula i, um tautomer da mesma, ou um sal farmaceuticamente aceitável, hidrato ou outro solvato do mesmo e método para o tratamento de cáncer em um mamìfero necessitado do mesmo e composição
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
CA2662538A1 (fr) * 2006-09-11 2008-03-20 Glaxo Group Limited Composes azabicycliques en tant qu'inhibiteurs de reabsorption de monoamines
EP2066642A1 (fr) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Inhibiteurs d'époxyde hydrolase soluble
PE20080888A1 (es) * 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008086014A2 (fr) * 2007-01-09 2008-07-17 Amgen Inc. Dérivés de bis-aryl amide et procédés d'utilisation
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
ES2483898T3 (es) 2007-06-08 2014-08-08 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
EP2152270B1 (fr) * 2007-06-08 2015-03-04 Janssen Pharmaceutica, N.V. Dérivés de piperidine/piperazine
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
JP5443342B2 (ja) 2007-06-08 2014-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
TWI452044B (zh) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
BRPI0816970A2 (pt) 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
SI2212282T1 (sl) * 2007-10-17 2012-01-31 Sanofi Sa Substituirani n-fenil-bipirolidin karboksamidi in njihova terapevtska uporaba
DK2212283T3 (da) * 2007-10-17 2011-12-19 Sanofi Sa Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
KR20100082349A (ko) * 2007-10-17 2010-07-16 사노피-아벤티스 치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도
EP2205558B1 (fr) * 2007-10-17 2012-07-25 Sanofi Amides de n-phényl-pyrrolidinylméthylpyrrolidine substitués et leur utilisation thérapeutique comme modulateurs du récepteur h3 de l'histamine
SI2206707T1 (sl) 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolkarboksamidna spojina ali njena sol
CA2704436C (fr) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derives imidazo[1,2-a]pyridine et leur utilisation comme modulateurs allosteriques positifs des recepteurs mglur2
EP2070916A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Dérivés de 2-aryl-thiazol-4-amides d'acide carboxylique, leur fabrication et leur utilisation en tant que médicament
EP2070925A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nouveaux dérivés de 2-thiazol-4-amides d'acide carboxylique substitués, leur fabrication et leur utilisation en tant que médicament
EP2070924A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nouveaux dérivés de 2-hetarylthiazol-4-amides d'acide carboxylique, leur fabrication et leur utilisation en tant que médicament
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
PE20100083A1 (es) 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
US20110318266A1 (en) * 2008-09-16 2011-12-29 Mccauley John A Phthalimide derivative metabotropic glutamate r4 ligands
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd ２−インドールアクリルアミド類縁体
WO2010043396A1 (fr) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Dérivés d’indole et de benzomorpholine en tant que modulateurs des récepteurs métabotropiques du glutamate
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
AR074466A1 (es) * 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
JP5642661B2 (ja) * 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
EP2404896A1 (fr) 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Dérivé de cyclohexane présentant un antagonisme du récepteur npy y5
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011060026A1 (fr) 2009-11-12 2011-05-19 Jansen Pharmaceutica Nv Dérivé de pipérazine-carboxamide utile en tant que modulateur de la faah (fatty acid amide hydrolase)
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
AR081908A1 (es) * 2010-05-11 2012-10-31 Sanofi Aventis N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas
TW201206939A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
EP2569294B1 (fr) * 2010-05-11 2015-03-11 Sanofi Bipyrrolidine carboxamides n-heteroaromatiques, leur preparation et usage therapeutique
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2661435B1 (fr) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. Dérivés 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683698B1 (fr) 2011-03-08 2017-10-04 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US9051265B2 (en) 2011-06-06 2015-06-09 The Scripps Research Institute N-benzylindole modulators of PPARG
WO2012170554A1 (fr) 2011-06-06 2012-12-13 Theodore Mark Kamenecka Modulateurs n-biphénylméthylindole de pparg
US9309227B2 (en) 2011-11-22 2016-04-12 The Scripps Research Institute N-biphenylmethylbenzimidazole modulators of PPARG
WO2013085957A1 (fr) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Dérivés de pipéridinyl-pyridazinyle substitué utiles comme inhibiteurs de scd 1
WO2013085954A1 (fr) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Dérivés de pipéridinyl-carboxamide substitué utiles en tant qu'inhibiteurs de scd 1
EP2852585A1 (fr) * 2012-05-11 2015-04-01 AbbVie Inc. Inhibiteurs de nampt
JP6293770B2 (ja) * 2012-11-05 2018-03-14 ナント ホールディングス アイピー，エルエルシー ヘッジホッグシグナル伝達経路阻害剤としての環状スルホンアミド含有誘導体
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
EP2961746B1 (fr) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Dérivés de phénylpyrazole en tant que puissants inhibiteurs de rock1 et rock2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (fr) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
US10016394B2 (en) 2014-04-16 2018-07-10 The Scripps Research Institute PPARG modulators for treatment of osteoporosis
WO2016008011A1 (fr) * 2014-07-16 2016-01-21 Novogen ltd Indoles fonctionnalisés et substitués utilisés en tant qu'agents anti-cancéreux
CN107108581B (zh) * 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
CA2960274A1 (fr) * 2014-09-10 2016-03-17 Epizyme, Inc. Composes carboxamides isoxazoles
CN108026039A (zh) * 2015-08-28 2018-05-11 格兰马克药品股份有限公司 作为RORγ调节剂的新型碳环化合物
RS60825B1 (sr) 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
CN108815167B (zh) * 2017-05-24 2021-04-13 四川晶华生物科技有限公司 一种化合物在制备治疗肿瘤的药物中的用途
TW202136238A (zh) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途
WO2022150962A1 (fr) * 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Inhibiteurs de protéase, leur préparation et leurs utilisations
CN115160269A (zh) * 2021-04-02 2022-10-11 北京大学 芳甲酰胺类衍生物作为nmdar的正性变构调节剂
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69522234T2 (de) * 1994-10-26 2002-05-16 Pharmacia & Upjohn Co., Kalamazoo Phenyloxazolidinone mit antimikrobieller wirkung
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
WO1997041097A2 (fr) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Nouveaux composes heterocycliques, leur procede de preparation, compositions pharmaceutiques les contenant et utilisation de ces composes dans le traitement du diabete et des maladies associees
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
AU757693B2 (en) 1997-07-16 2003-03-06 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
CA2309121A1 (fr) * 1997-11-07 1999-05-20 Schering Corporation Phenyl-alkyl-imidazoles utilises comme antagonistes du recepteur h3
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
AU3126700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE60017115T2 (de) * 1999-02-10 2005-12-08 Mitsubishi Pharma Corp. Amid-derivate und deren medizinische verwendung
TR200102911T2 (tr) * 1999-04-09 2002-01-21 Astrazeneca Ab Adamantan türevleri.
EP1173438A1 (fr) 1999-04-16 2002-01-23 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation
JP2002543200A (ja) 1999-04-30 2002-12-17 ニューロゲン コーポレイション ９Ｈ−ピリミド［４、５−ｂ］インドール誘導体：ＣＲＦ１特異性リガンド
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
SE9901875D0 (sv) * 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
EP1194146B1 (fr) 1999-06-18 2006-07-19 Merck & Co., Inc. Derives d'arylthiazolidinedione et d'aryloxazolidinedione
CA2378878A1 (fr) 1999-07-29 2001-02-08 Jeffrey Thomas Mullaney Benzofurylpiperazines et benzofurylhomopiperazines: antagonistes de la serotonine
CA2383781A1 (fr) 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Derives de sulfonylcarboxamide, leur procede de production et leur utilisation comme medicaments
WO2001083451A1 (fr) 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Nouveaux composés bicycliques
JP2004507456A (ja) 2000-05-11 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
EP1289526A4 (fr) 2000-05-30 2005-03-16 Merck & Co Inc Agonistes du recepteur de la melanocortine
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
WO2002006278A1 (fr) * 2000-07-17 2002-01-24 Ranbaxy Laboratories Limited Derives d'oxazolidinone utilises en tant qu'antimicrobiens
HUP0302966A2 (hu) * 2000-07-31 2003-12-29 Smithkline Beecham P.L.C. Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
JP2002338537A (ja) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
WO2002098839A1 (fr) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides et procede de preparation de ceux-ci
WO2002098871A1 (fr) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Phenylcarboxamides et procede de preparation correspondant
WO2002099388A2 (fr) * 2001-06-07 2002-12-12 Merck & Co., Inc. Benzodiazepines antagonistes de bradykinine
DE10142734A1 (de) 2001-08-31 2003-03-27 Aventis Pharma Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2483306A1 (fr) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive
JP2004175739A (ja) * 2002-11-28 2004-06-24 Tanabe Seiyaku Co Ltd 医薬組成物

Also Published As

Publication number Publication date
WO2004072025A2 (fr) 2004-08-26
RU2005128551A (ru) 2006-02-10
TW200510297A (en) 2005-03-16
RS20050666A (sr) 2007-12-31
AU2004212145B2 (en) 2010-06-17
CN100506792C (zh) 2009-07-01
UA86760C2 (ru) 2009-05-25
PA8595901A1 (es) 2004-09-16
ZA200506369B (en) 2006-07-26
OA13027A (en) 2006-11-10
CA2516118A1 (fr) 2004-08-26
BRPI0407504A (pt) 2006-02-14
NO20054220L (no) 2005-10-28
ECSP055967A (es) 2006-01-16
PE20040952A1 (es) 2005-02-08
WO2004072025A3 (fr) 2004-12-23
NO20054220D0 (no) 2005-09-12
MXPA05008449A (es) 2006-05-25
CO5690548A2 (es) 2006-10-31
CN1774418A (zh) 2006-05-17
KR20050101215A (ko) 2005-10-20
UY28186A1 (es) 2004-09-30
MA27735A1 (fr) 2006-02-01
EP1597228A2 (fr) 2005-11-23
AU2004212145A1 (en) 2004-08-26
PL378065A1 (pl) 2006-02-20
DE10306250A1 (de) 2004-09-09
TNSN05194A1 (en) 2007-06-11
AR044496A1 (es) 2005-09-14
HRP20050710A2 (en) 2006-07-31
NZ541823A (en) 2009-01-31
JP2006517563A (ja) 2006-07-27

Similar Documents

Publication Publication Date Title
TW200510297A (en) Substituted n-aryl heterocycles, process for their preparation and their use as medicaments
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
TW200610527A (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
TW200510417A (en) Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4, 7-dione derivatives, processes for their preparation and their use as medicaments
MY135902A (en) SUBSTITUTED HEXAHYDROPYRAZINO [1, 2-a] PYRIMIDINE-4, 7-DIONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
MY124122A (en) Heterocyclic derivatives
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
MXPA05008690A (es) Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
UA94901C2 (ru) Антибактериальные производные пиперидина
GB9715894D0 (en) Heterocyclic derivatives
MY141197A (en) Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
WO2004100865A3 (fr) Nouveaux derives de benzimidazole
PL343706A1 (en) Heterocyclic derivatives which inhibit factor xa
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ZA200103106B (en) Bile-acid substituted phenyl alkenoyl guanidines, method for the production thereof, use thereof as medicaments or diagnostic agents and medicaments that contain them.
MY139107A (en) Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments.
GB9809349D0 (en) Heterocyclic derivatives
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
TW200407282A (en) Urea- and urethane-substituted acylureas, process for their preparation and their use
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
NO20053809L (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
SE0202693D0 (sv) Compounds